Elite Pharmaceuticals Inc (QB) (ELTP) News

I meant to say Entering Tuesday-Thursday PR zone

$3 $5 buyout

1. Methotrexate $63.4M
2. Tylenol with Codeine $43M
3. Percocet $500M
4. Norco$477M
5. Methadone 30M
6. Vyvanse$5.10 Billion

7. Dopamine Agonist $12M

8. OxyContin $720M

9. Concerta $1.16 Billion

https://www.barchart.com/stocks/quotes/ELTP/opinion

According to the chartist we should go up today,
we have a bit of a pennant going back to the 13th, and have had three lul , or flat days

Entering Tuesday-Thursday or zone.

What was it?

Elite has been working on generic Concerta for a long time. My guess is that is where a lot of Elite’s R&D dollars are being spent. A positive BE study for Concerta would be a major catalyst for ELTP. It is a difficult product to replicate, hopefully Elite can do it.

Hi James, I like your way of thinking - this is indeed a discovery.

We see how Nasrat was able to find API for Adderall where other manufacturers are dry

Kudos !

Agreed. I also think Concerta would be huge. Would be nice to see a positive BE trial soon.

Lots of discussion about generic OxyContin today, but the bigger potential approval is generic Vyvanse. According to the last conference call Elite has to have their API supplier approved by the FDA. That tells us the Elite’s supplier is different than any other manufacturer’s API source for generic Vyvanse. That’s a big deal. All the other manufacturers are having shortages. If Elite’s supplier passes the FDA hurdle and Elite gets approval (neither is a sure thing), Elite just might be the only generic Vyvanse not constantly on back order. 🍀

Green Green Green

Purdue and Sacklers.......... slimeballs IMO~!

Anything for money...........

$ELTP baby~!

lol… first and foremost Elite needs to obtain FDA approval… or this whole discussion is moot.

IMHO, Elite has absolutely no reason to partner with Purdue (Knoa) And vice versa. They have no reason to partner with us. Each company has their own manufacturing capabilities. As one of the first few generics the product will practically market itself. Knoa (Purdue) might want to sell the product they currently manufacture under a generic label to preserve market share. Perhaps an authorized generic company like Prasco (that does not have manufacturing capability) might be interested in that.

Right?

Def had our time in the PPS wilderness but recent movement has been excellent. More to come, I expect.

I believe we will stay around the 40 wall until we get a new PR - and as we get closer to November in General, we will see the PPS starting to climb - from the next PR till med October... Very much like what we saw before the August 15th Teleconference - the only difference is that we have many fruits that are ripe and ready to fall off the tree - and these are the short killers...

Thanks for that. Also the part about any blocking patents. That should be removed now. Meaning not blocked. We may be in good shape.

When I run the decision tree and pros and cons and what generates the most quickest revenue. The answer has been to partner with Purdue. I am not saying this is going to happen or that I love it.

But when you calculate what brings the most quickest guaranteed revenue , that was the answer.

However this info you provided makes me think about it more.

I don't care who files 1st, 2nd, or 3rd. I'm interested in having it approved. Approval is what is necessary, then we deal with the 1st, 2nd, and 3rd.

the 40 wall
does it break thru before or after lunch
or in the power hour

According to this link from the FDA, several companies can be first to file.

https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvals

just scroll down

Santa Clause is coming to town !!!!!

Short's hope Im not right,
Its about to get REAL !!!!


$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

THX James

Anecdotal info: at Cardinal Naltrexone by precision dose in unit dose packages is in stock. Sun brand is in stock in bulk packaging. All others are back ordered. Vyvanse generic remains extremely difficult to order. Most strengths are unavailable from Cardinal. Brand name product is in stock. Adderall and Adderall XR are intermittently available from several manufacturers. The pharmacy orders whichever one is available on a given day.

Why do you post BS You have no idea if that’s true

As long as he’s not talkin about Mikah and dollar land in a year

I guess a double in a month is not good enough for some people.

Another example of snap judgement being completely wrong. At least I can count on that to be consistent. The day didn't start out like this at all - started off great. Who knows when the November run will pick back up. We all know it's coming. Be wary of posts that are consistently wrong, typically taken out of context, or refusing to acknowledge positive information.

Perhaps October will be a better month for small caps...

Hi NASDAQ2020, Purdue sued Accord first and sued Elite second. This saved Elite a lot of legal expenses, but indicates that Purdue saw Accord as the more imminent threat. My guess is they get to market ahead of Elite. It is still a needle mover if Elite crosses the line second.

Its all adding up !
$3 $5 buyout

1. Methotrexate $63.4M
2. Tylenol with Codeine $43M
3. Percocet $500M
4. Norco$477M
5. Methadone 30M
6. Vyvanse$5.10 Billion

7. Dopamine Agonist $12M

8. OxyContin $720M

9. Concerta $1.16 Billion

Elites OxyContin could be approved in 2 weeks.
Accord needs to get goin’

https://www.barchart.com/stocks/quotes/ELTP/opinion

HammerTime ELTP

Do the math and add upthe massive amounts of IMS marketvalue we are entering.

Its about to Get Real!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

$5.1 Billion dollar drug approval and launch Imminent

Nasrat about to DropTheHammer !!!!!!!!!!!!!!!!!!!!!1

ELTP

yOu should not have sold at $0.15 lol

Actually it's not consistent at all. Have you paid any attention to the past 30 days? Apparently not. Your "opinion" seems as inconsistent as previous posts stating that you "are out at .15 cents". Clearly we are way above that, and the only consistency is the long-term trend upwards - along with catalysts leading into a huge November timeframe.

I’ve been asked to leave this board and will gladly do so. Good luck to all. Go MIKAH !

Why - because Nasrat said so under the protection of the safe harbor act

ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
Bullish

Day starts off with bud much lower than the ask. Seems to be consistent. Another down day I’m sad to say My opinion

float went over a billion.

Please stop telling people that elite will ever be worth 5 Billion dollars. That ship sailed when the float went over a billion.

Nasrat said it in the last cc. Our only limitation is the dea quotas. And our team does a wonderful job at extending the quotas.

I hope Kirko reads the board, I've sent him a lot of leads over the past year

This type of information has to go to Diane.

These shortages are real. The biggest challenge is getting quota. I’m sure Elite has no problem selling all they can produce. I am also sure Elite is doing everything they can to get their quota increased.

Another target for Kirko, this just came out,
new this decade. lol


https://www.msn.com/en-us/health/other/pharmacies-in-central-illinois-face-medicine-shortage/ar-AA1r0vke

Hi Sleuth, I don’t see Elite and Knoa (Purdue) making any deals regarding OxyContin. My guess is Elite gets approval and brings their generic to market, probably after Accord does the same. Knoa (Purdue) will likely make a deal with another company to market an authorized generic. Under this scenario I could see Elite taking 20% of the market. Of course, my guess is no better than yours lol. We will see what happens. Good luck.

News Imminent

Upcoming ELTP Catalysts:

X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco/Burel Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
__15. Obtain Full ownership of Adderall IR $ 335 Million from MIKAH
__16. Obtain Full ownership of Adderall XR $ 1.56 Billion from MIKAH
X 17. Vigabatrin Approval $233 Million
X 18. Pyros Vigabatrin -settle VigPoder trade mark challenge and LAUNCH
X 19. Generic Methotrexate Antimetabolite- Approval
X 20. Launch generic Methotrexate $63.4 Million
X 21. $50+ million in yearly revenues
X 22. Lowest PE ratio for OTC Healthcare sector
X 23. Become the ONLY company showing rapid growth on the OTC while being profitable
X 24. Put Opioids back on the Table- due to reduced risk of opioid litigation
X 25. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__26. Generate revenues over $20 million/quarter
__27. Final Approval of New Manufacturing Facility/Expansion
__28. Double output of manufacturing and packaging facilities
__29. Launch approved generic Tylenol with Codeine $45 Million
__30. Launch approved generic Norco - hydrocodone acetaminophen IMS $477 Million
__31. Launch approved generic Percocet - oxycodone acetaminophen IMS $500 Million
__32. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
__33. Generic Vyvanse Approval and Launch
__34. Generic Concerta- FDA submission $1.2 BILLION
__35. $100 million in yearly revenue
__36. Generic OxyContin Tentative Approval $720 Million
__37. Elite prevail over Purdue in Generic OxyContin infringement suit - second 6 month stay - active Accord/Purdue suit causing delay
__38.Launch generic OxyContin $720 Million
__39. Resume R&D on SequestOx Abuse Deterrent Oxycodone
__40. European distribution - Dexcel partnership approval by Israeli Health
__41. $200 million in yearly revenue
__42. Patented Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__43. Undisclosed Mikah ANDA(s)
__44. Undisclosed ANDAs/NDAs
__45. Generic Concerta Approval and Launch
__46. DollarLand PPS
__47. Big Pharma bid
__48. UpList to the NASDAQ Exchange
__49. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
Bullish

"Soon" with Elite is counted in years

He’s waiting on $3 to $5 dollars per share. Could take a year and a half.

I think I will sell the remaining shares if these is no news soon

Welcome to the club

I own elite so not sure what any one means by a case for not owning it.